贞芪扶正胶囊联合艾米替诺福韦对慢性乙型肝炎的疗效观察  

Observation on the efficacy of Zhenqi Fuzheng capsule combined with tenofovir amibufenamide in the treatment of chronic hepatitis B

作　　者：华忠 Hua Zhong(Department of Liver Diseases,Wuxi Fifth People's Hospital,Wuxi 214004,China)

机构地区：[1]无锡市第五人民医院肝科,无锡214004

出　　处：《中华肝脏病杂志》2024年第S1期10-13,共4页Chinese Journal of Hepatology

摘　　要：目的评价贞芪扶正胶囊联合艾米替诺福韦(TMF)与单用TMF为对照治疗慢性乙型肝炎对患者外周血淋巴细胞免疫功能及抑制HBV复制的影响。方法将70例CHB患者在护肝治疗基础上,随机分为治疗组和对照组,治疗组36例,对照组34例。治疗组为口服TMF 25 mg,次/d,联合贞芪扶正胶囊,每次1.4 g,3次/d;对照组为口服TMF 25 mg,次/d,两组疗程均为48周。计数资料比较用χ^(2)检验,计量资料用t检验。结果外周血淋巴细胞免疫功能指标:治疗48周时,CD4^(+)细胞、CD4^(+)/CD8^(+)比值、自然杀伤细胞数值,治疗组均高于对照组(P值均<0.05)。血清HBeAg阴转率:治疗48周时,治疗组50.0%,对照组26.3%,两组比较,差异有统计学意义(χ^(2)=6.98,P<0.05)。HBV DNA载量:治疗24周及48周时,两组HBV DNA载量下降值与基线HBV DNA值比较,差异均有统计学意义(P值均<0.05)。结论贞芪扶正胶囊联合TMF治疗慢性乙型肝炎,在调节免疫功能方面优于单用TMF,同时在降低HBV DNA载量及血清HBeAg阴转率方面也优于单用TMF。Objective To evaluate the effect of Zhenqi Fuzheng capsule combined with tenofovir amibufenamide(TMF)and TMF monotherapy on the immune functions of peripheral blood lymphocytes and the inhibition of HBV replication for chronic hepatitis B(CHB).Methods Seventy CHB cases were randomly divided into a treatment and a control group based on the hepatoprotective therapy,with 36 and 34 cases in the treatment and control groups,respectively.The treatment group was treated with oral tenofovir amibufenamide 25 mg once a day,in combination with Zhenqi Fuzheng capsule 1.4 g three times a day.The control group was treated with oral TMF 25 mg once a day.The treatment course was compared at 48 weeks in both groups.Results Peripheral blood lymphocyte immune function indicators:The CD4^(+)cells,CD4^(+)/CD8^(+)ratio,and natural killer cell values in the treatment group were higher than those in the control group at 48 weeks of treatment(P<0.05).The treatment group had a serum HBeAg negative conversion rate of 50.0%at 48 weeks of treatment,while the control group had a rate of 26.3%.The difference between the two groups was statistically significant(χ^(2)=6.98,P<0.05).HBV DNA load:The decrease in HBV DNA load in the two groups was statistically significant compared with the baseline HBV DNA value at 24 and 48 weeks of treatment(P<0.05).Conclusion Zhenqi Fuzheng capsules combined with TMF therapy are superior for regulating immune function and reducing HBV DNA load and HBeAg-negative seroconversion rates compared to TMF alone.

关 键 词：慢性乙型肝炎 免疫 治疗 贞芪扶正胶囊 艾米替诺福韦 

分 类 号：R259[医药卫生—中西医结合] R512.6[医药卫生—中医内科学]